6 February 2023 Quebec becomes first province to cover BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s macroglobulinemia
8 April 2021 BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
